Contact Us
join our enewsletter  |   translate
Donate
Print Page    A A

Nintedanib

Status
Phase 3
Condition
Other Related Conditions
Intervention Type
Oral Drug
Funder Type
Industry
The main objective is to assess long term safety of treatment with oral nintedanib in patients with Systemic Sclerosis associated Interstitial Lung Disease (SSc-ILD).

NCT03313180

 

footer_txt_bblBook a PFF Ambassador for your event.   Call 844.TalkPFF >


The Pulmonary Fibrosis Foundation rates among top charities in the U.S. The PFF has a three-star rating from Charity Navigator and is a Better Business Bureau accredited charity. The Foundation has met all of the requirements of the National Health Council Standards of Excellence Certification Program®.

Charity Navigator Logobetter business bureau logo NHCSEP_PFF Giving Star

PRIVACY POLICY    TERMS OF USE

© 2019 Pulmonary Fibrosis Foundation   |   230 East Ohio Street, Suite 500, Chicago, Illinois 60611

p. 888.733.6741   |   f. 866.587.9158   |   info@pulmonaryfibrosis.org
Website created by KlearSky
Join Our Monthly eNewsletter

PRIVACY POLICY    TERMS OF USE

© 2019 Pulmonary Fibrosis Foundation   |   230 East Ohio Street, Suite 500, Chicago, Illinois 60611

p. 888.733.6741   |   f. 866.587.9158   |   info@pulmonaryfibrosis.org
Website created by KlearSky

Join Our Monthly eNewsletter
Subscribe to receive the most current news and updates from the Pulmonary Fibrosis Foundation.